Aug 12 2014
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that National Government Services (NGS) has issued a positive coverage decision for Posterior Tibial Nerve Stimulation (PTNS) for the treatment of urinary urgency, urinary frequency and urge incontinence associated with overactive bladder (OAB). Coverage for the proprietary Urgent PC® device was effective August 10, 2014.
NGS, a Medicare Administrative Contractor, provides medical and drug benefits to approximately 10 million Medicare beneficiaries in the states of New York, Illinois, Massachusetts, Wisconsin, Minnesota, Connecticut, Maine, New Hampshire, Rhode Island and Vermont.
There are over 50 million Medicare beneficiaries in the United States and all of these individuals now have access to PTNS, the only non-drug, non-surgical treatment for those who suffer from the symptoms of overactive bladder. Urgent PC is a recommended third line treatment within the OAB treatment guidelines for patients who have not responded or cannot tolerate behavioral intervention and pharmacologic agents. The treatment guidelines are issued jointly by the American Urology Association (AUA) and Society for Urodynamics and Female Urology (SUFU).
"We are pleased with the NGS positive coverage decision and excited that access to PTNS is now in place for all Medicare beneficiaries across the country. Through the efforts and collaboration of an independent physician coalition from across all ten states, NGS was able to recognize the medical necessity of PTNS and its value to patients and physicians trying to manage the symptoms of OAB," said Dan Merz, Vice President of Healthcare Affairs. "We look forward to bringing PTNS back to the many patients who had coverage in the past and to a whole new group of patients in New York and Connecticut who have never had access."
The Company will initiate increased sales and marketing efforts for PTNS in markets served by NGS during the remainder of fiscal 2015, with the Company expecting a meaningful impact on U.S. Urgent PC sales starting in fiscal 2016. The Company expects to update its fiscal 2015 guidance when it reports second quarter results.